Ligand Pharmaceuticals Incorporated (LGND)vsVertex Pharmaceuticals Inc (VRTX)
LGND
Ligand Pharmaceuticals Incorporated
$237.00
+0.46%
HEALTHCARE · Cap: $5.12B
VRTX
Vertex Pharmaceuticals Inc
$446.83
-1.60%
HEALTHCARE · Cap: $114.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 4351% more annual revenue ($12.22B vs $274.48M). LGND leads profitability with a 55.9% profit margin vs 35.5%. LGND appears more attractively valued with a PEG of 1.53. VRTX earns a higher WallStSmart Score of 68/100 (B-).
LGND
Strong Buy67
out of 100
Grade: B-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.9%
Fair Value
$160.49
Current Price
$237.00
$76.51 premium
Margin of Safety
+52.4%
Fair Value
$949.55
Current Price
$446.83
$502.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Earnings expanding 103.2% YoY
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LGND
The strongest argument for LGND centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 55.9% and operating margin at 33.6%. Revenue growth of 14.1% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LGND carries more volatility with a beta of 1.04 — expect wider price swings.
LGND is growing revenue faster at 14.1% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (68/100 vs 67/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?